Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
Therapeutics and Clinical Risk Management
Volume Volume 19, Issue -, Pages 77-96
Publisher
Informa UK Limited
Online
2023-01-22
DOI
10.2147/tcrm.s352008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of fibroblast growth factor 21 in non‐alcoholic fatty liver disease in guinea pigs
- (2022) Julie Hviid Klaebel et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis
- (2022) Haiying Tang et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications
- (2022) Ilias D. Vachliotis et al. DIABETES OBESITY & METABOLISM
- FGF21 Reduces Lipid Accumulation in Bovine Hepatocytes by Enhancing Lipid Oxidation and Reducing Lipogenesis via AMPK Signaling
- (2022) Yezi Kong et al. Animals
- Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
- (2022) Tobias Puengel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial
- (2022) Somayyeh Asghari et al. Nutrients
- Combination Therapies for Nonalcoholic Fatty Liver Disease
- (2022) Evangelia S. Makri et al. Journal of Personalized Medicine
- Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications
- (2022) Leigang Jin et al. Annual Review of Pharmacology and Toxicology
- Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH
- (2022) Susanna C. Larsson et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
- (2021) Qi Pan et al. EBioMedicine
- Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
- (2021) Stergios A. Polyzos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia
- (2021) Daniel J Rader et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway
- (2021) Yi-kuan Wu et al. ACTA PHARMACOLOGICA SINICA
- Nonalcoholic fatty liver disease: lifestyle and quality of life
- (2021) Ilias Vachliotis et al. Hormones-International Journal of Endocrinology and Metabolism
- The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
- (2021) Jeffrey V. Lazarus et al. JOURNAL OF HEPATOLOGY
- Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice
- (2021) Kota Yano et al. LABORATORY INVESTIGATION
- The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
- (2021) Tom H Karlsen et al. LANCET
- Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2021) Xinyue Li et al. Journal of Diabetes Research
- Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
- (2021) Xiaoxue Long et al. Frontiers in Endocrinology
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates
- (2020) Aoyuan Cui et al. DIABETES
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
- (2020) Evangelia Makri et al. ARCHIVES OF MEDICAL RESEARCH
- Relationship between dietary patterns and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
- (2020) Shirin Hassani Zadeh et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes
- (2019) Diana Barb et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement
- (2019) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?
- (2019) Marta Flisiak-Jackiewicz et al. Advances in Medical Sciences
- A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation
- (2018) Hye Jin An et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways
- (2018) Kyong Joo Lee et al. Gut and Liver
- FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation
- (2018) Jun-yan Li et al. INFLAMMATION
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Sleeve gastrectomy attenuates high fat diet-induced non-alcoholic fatty liver disease
- (2018) Erli Pei et al. Lipids in Health and Disease
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes
- (2017) Mariya Markova et al. GASTROENTEROLOGY
- Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation
- (2017) Laurie R. Braun et al. GROWTH HORMONE & IGF RESEARCH
- Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013)
- (2017) Hye Jin An et al. Oncotarget
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Emerging and future therapies for nonalcoholic steatohepatitis in adults
- (2016) Gesthimani Mintziori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice
- (2016) Qi Gong et al. HEPATOLOGY
- Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men
- (2016) Hirokazu Taniguchi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD
- (2016) Claudio Pirozzi et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Adipokines in nonalcoholic fatty liver disease
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Sex-specific metabolic interactions between liver and adipose tissue in MCD diet-induced non-alcoholic fatty liver disease
- (2016) Yun-Hee Lee et al. Oncotarget
- CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis
- (2016) Jong-Gil Park et al. Scientific Reports
- Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice
- (2016) Fenni Rusli et al. Scientific Reports
- Gastric bypass surgery is protective from high-fat diet-induced non-alcoholic fatty liver disease and hepatic endoplasmic reticulum stress
- (2015) J. D. Mosinski et al. Acta Physiologica
- Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet
- (2015) Naoki Tanaka et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients
- (2015) Xiaoyan Zhang et al. Cardiovascular Diabetology
- Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis
- (2015) Chrysi Koliaki et al. Cell Metabolism
- miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21
- (2015) Junjie Xiao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis
- (2015) Mei Yang et al. PLoS One
- Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
- (2014) K. R. Markan et al. DIABETES
- Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
- (2014) Ffolliott M. Fisher et al. GASTROENTEROLOGY
- Fibroblast Growth Factor 21 Is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-induced Hepatic Steatosis
- (2014) Shan Jiang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Single Nucleotide Polymorphism rs499765 Is Associated with Fibroblast Growth Factor 21 and Nonalcoholic Fatty Liver Disease in a Chinese Population with Normal Glucose Tolerance
- (2014) Shan Jiang et al. Journal of Nutrigenetics and Nutrigenomics
- Prevention and reversal of hepatic steatosis with a high-protein diet in mice
- (2013) Sonia C. Garcia-Caraballo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Circulating Levels of FGF-21 in Obese Youth: Associations With Liver Fat Content and Markers of Liver Damage
- (2013) Cosimo Giannini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure
- (2013) Annika Mutanen et al. JOURNAL OF HEPATOLOGY
- Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease
- (2013) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease
- (2013) Anna Alisi et al. PLoS One
- Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice
- (2013) Yongmei Yu et al. Scientific Reports
- Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction
- (2012) Justin A. Fletcher et al. Applied Physiology Nutrition and Metabolism
- Fibroblast growth factor 21 is induced by endoplasmic reticulum stress
- (2012) Frank G. Schaap et al. BIOCHIMIE
- Fibroblast Growth Factor 21 (FGF-21) and Its Relation to Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver in Children: A Longitudinal Analysis
- (2012) Thomas Reinehr et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
- (2012) Jiayun Shen et al. JOURNAL OF HEPATOLOGY
- High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China
- (2012) Huating Li et al. JOURNAL OF HEPATOLOGY
- Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor
- (2012) W. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently
- (2011) Xuesong Li et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
- (2011) S. L. Samson et al. DIABETOLOGIA
- Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat
- (2011) Niina Matikainen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study
- (2011) Hongmei Yan et al. PLoS One
- Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
- (2010) f. M. Fisher et al. DIABETES
- Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
- (2010) Yusuf Yilmaz et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
- (2010) Jody Dushay et al. GASTROENTEROLOGY
- Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis
- (2010) HEPATOLOGY RESEARCH
- Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
- (2010) Huating Li et al. JOURNAL OF HEPATOLOGY
- Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway
- (2010) Mary D. L. Chau et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
- (2009) Stergios A. Polyzos et al. DIABETES OBESITY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More